RxDoctor Payments Data

Krystal Patrick

Psychiatric/Mental Health · Tuscaloosa, ALNPI 1558997247

Payments from drug & device makers

$4,098in general payments, 2019–2025

Across 204 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$864
  • Otsuka America Pharmaceutical, Inc.$792
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$581
  • Supernus Pharmaceuticals, Inc.$368
  • Johnson & Johnson$316
  • Takeda Pharmaceuticals U.S.A., Inc.$250
  • plus $926 from 10 others

What the payments were for

  • Food & beverage$4,098100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,098 in reported general payments places this provider in the 75th percentile of 378 psychiatric/mental health providers in Alabama.

See all psychiatric/mental health providers in Alabama

Medicare billing

Part B allowed, 2024
$28,933
Medicare patients
40
Services billed
354

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl45$93,078
Duloxetine Hcl53$1,835
Trazodone Hcl45$1,523
Quetiapine Fumarate66$1,266
Bupropion XlBupropion Hcl21$855
Mirtazapine34$815
Aripiprazole20$706
Lamotrigine39$606
Buspirone Hcl48$567
Sertraline Hcl21$307
Doxepin Hcl17$290
Fluoxetine Hcl24$271
Escitalopram Oxalate20$203
Donepezil Hcl16$140
Benztropine Mesylate11$139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$864$93,07845 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 378 psychiatric/mental health providers in Alabama.

Other psychiatric/mental health in Tuscaloosa

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →